ArticleApplied biochemistry and biotechnology2026
CircPDXDC1 Induces Mitochondrial Dysfunction and Autophagy Dysfunction in Acute Myocardial Infarction by Promoting ELAVL1 Ubiquitination.
Article in Applied biochemistry and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
The influence of circRNAs on the pathological process of acute myocardial infarction (AMI) has not been entirely clarified. This study was to systematically screen the aberrantly expressed circRNAs in AMI and to reveal the molecular mechanism of circPDXDC1 in AMI and its interactions with the RNA-binding protein ELAVL1. Based on the GSE160717 dataset (GEO database), differentially expressed circRNAs were screened using the Limma R package and visualized by volcano plots with heat maps. The stability of circPDXDC1 was verified by actinomycin D treatment, RNase R digestion, and divergent/convergent primer PCR. OGD-treated AC16 and HL-1 cell models and AMI mouse model were constructed. siRNA knockdown, overexpression vector transfection, and lentiviral intervention techniques were used to assess mitochondrial function and autophagy in combination with LDH/CK-MB assay, ROS/ATP/MMP analysis, MDC staining and Western blot. The interaction mechanism between circPDXDC1 and ELAVL1 was analyzed by RNA-pull down, RIP, FISH, and ubiquitination experiments. Bioinformatics analysis identified circPDXDC1 (hsa_circ_0038011) to be significantly highly expressed in myocardial tissues of AMI patients and models, with a high stability to actinomycin D and RNase R. circPDXDC1 downregulation significantly ameliorated OGD-induced cellular injury, as evidenced by reduced LDH/CK-MB release, decreased ROS/MDA levels, ATP/MMP restoration, and reversal of autophagy marker (ATG5/Beclin-1/p62). circPDXDC1 bound to ELAVL1 and promoted its ubiquitinated degradation, while ELAVL1 overexpression antagonized OGD-induced mitochondrial dysfunction and autophagy hyperactivation. circPDXDC1 knockdown significantly attenuated AMI in mice by upregulating ELAVL1. CircPDXDC1 exacerbates mitochondrial dysfunction and autophagy dysregulation by targeting the ELAVL1 ubiquitination degradation.
Indexed as
Identifiers
41484747What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.